08 DEC 2017: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) received another Notice of Allowance for a new patent covering the use of cell phones and watches to analyze movement disorders such as Parkinson’s disease. The new Notice of Allowance is for an application entitled “Parkinson’s disease drug or medication titration, delivery system, and method.”
GLNT’s patent portfolio extensively covers the use of motor symptom data collected from movement disorder monitoring devices such as its Kinesia™ [http://www.glneurotech.com/kinesia] technology, which provides wearable, objective, and automated assessment of movement disorder symptoms. This newly allowed patent will further expand GLNT’s portfolio of over 20 patents by covering the monitoring of the progression of Parkinson’s disease using commonly available devices. “By using existing Apple® or Android™* smart phones along with smart watches/fitness trackers, doctors and patients will have a lower cost alternative to evaluate and change therapy prescriptions to optimize patient treatment,” stated Dustin Heldman, GLNT’s Vice President and COO.
According to GLNT Executive VP and General Counsel, Brian Kolkowski, “GLNT’s patents include systems and methods of external movement and/or physiological sensors to help clinicians monitor patients and optimize medication regimens in the clinic as well as titration of those drug therapies in real-time throughout the day as patients perform activities of daily living in their homes. This newly allowed patent covers measuring severity of symptoms by monitoring tremor, bradykinesia, rigidity, and dyskinesia with a cell phone and/or wrist-worn device and transmitting the data by a radio signal using devices generally available to most movement disorder patients. Thus, GLNT’s new patent not only covers the transmission from a cell phone to a clinician’s computer where the results can be scored, but also the transmission from a wrist-worn device to a cell phone for automatic scoring as well.”
This patent continues to protect the work on movement disorders monitoring that was started about 2003 by GLNT’s predecessor company, Cleveland Medical Devices. GLNT is currently using this technology to provide services to numerous pharmaceutical and medical device companies around the world to help them improve and titrate their products and obtain data on their products efficacy with patients as well, and hopes to expand the use of this technology affordably to the vast majority of Parkinson’s patients and their clinicians who desire to track their symptom severity in real-time on a daily basis.
The Kinesia product line has been designed to help individuals with movement disorders such as Parkinson’s disease and essential tremor. Providing easy to understand data to the doctor and patient can help with therapy modifications, which can improve the patient’s quality of life in hours or days, rather than the many months or years which the current standard of practice of infrequent doctor’s visits usually provides.
About Great Lakes NeuroTechnologies
Great Lakes NeuroTechnologies [http://www.glneurotech.com] is committed to pioneering innovative biomed technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world. Kinesia is a trademark of Great Lakes NeuroTechnologies Inc. of Valley View, OH.
Dustin A. Heldman, Ph.D., VP and COO, 216-361-5410 – dheldman@GLNeuroTech.com
* Apple is a registered trademark of Apple Inc., and Android is a trademark of Google LLC.